MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma May 17, 2018
MabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand Viewing May 7, 2018
MabVax Therapeutics to Present an Interactive Live Webcast at VirtualInvestorConferences.com Apr 30, 2018
MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting Apr 18, 2018
MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements Apr 13, 2018
MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting Mar 15, 2018
MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement Mar 6, 2018
